natgillin/translations-raw huggingface dataset:
Balance disorder, headache 
Bolezni živčevja motnje ravnotežja, glavobol konvulzije, somnolenca
Discard the Turbospin inhaler after the completion of a treatment pack. 
Inhalator Turbospin zavrzite, ko porabite pakiranje zdravila.
Posology 
Ustnik
Do not stop your treatment early unless your doctor says you can. 
Če ste vi/vaš otrok prenehali uporabljati zdravilo Colobreathe Ne prenehajte z zdravljenjem, razen če vam zdravnik naroči, da lahko.
Therefore, dose adjustment in low age groups is considered not necessary. 
Zato ni videti, da bi mlajši bolniki potrebovali prilagojen odmerek.
Colobreathe 1,662,500 IU inhalation powder, hard capsules 
Colobreathe 1.662.500 i.e. prašek za inhaliranje, trde kapsule
• Toothache 
• tesnoba,
Bronchospasm or coughing may occur on inhalation. 
Po inhaliranju se lahko pojavi bronhospazem ali kašelj.
The rinse should not be swallowed. 
Vode, s katero izpirate, ne smete pogoltniti.
Do not try to loosen the capsule by repeatedly pressing the piston. 
Odstranite pokrovček tako, da ga nežno povlečete.
Skin rash may also indicate hypersensitivity and if this occurs treatment should be withdrawn. 
Tudi kožni izpuščaj lahko nakazuje preobčutljivost.
Haemoptysis 
Tobramicin
• Nose bleeds, catarrh (mucus in your nose, which may make you feel blocked up), 
• krvavitev iz nosu, katar (sluz v nosu, zaradi katere čutite zamašenost), izkašljevanje goste zelene sluzi, bolečina v žrelu in sinusih,
Immune system disorders 
Bolezni imunskega sistema preobčutljivost na zdravilo
Contents of the pack and other information 
Shranjevanje zdravila Colobreathe Vsebina pakiranja in dodatne informacije
Colobreathe 1,662,500 IU inhalation powder, hard capsules colistimethate sodium 
Colobreathe 1.662.500 i.e. prašek za inhaliranje, trde kapsule natrijev kolistimetat
Chest pain, dyspnoea exacerbated, pharyngolaryngeal pain, epistaxis, sputum purulent, abnormal chest sound, increased upper airway secretion 
šumi v pljučih bolečina v prsnem košu, poslabšanje dispneje, faringolaringealna bolečina, epistaksa,
Colistimethate sodium is converted to the base in vivo. 
Biotransformacija Natrijev kolistimetat se in vivo pretvori v kolistin.
Ear and labyrinth disorders 
vključno z motnjami labirinta tinitus kongestija ušesa
• Sleepiness 
• zasoplost,
Colobreathe 1,662,500 IU inhalation powder colistimethate sodium 
Colobreathe 1.662.500 i.e. prašek za inhaliranje natrijev kolistimetat samo za inhaliranje
Medication error 
NAČIN IZDAJANJA ZDRAVILA
You may see a small amount of powder released from the capsule chamber after the capsule is pierced, this is normal. 
Po prebodu kapsule boste morda videli, kako se bo iz komore inhalatorja sprostil oblaček praška.
Package leaflet: Information for the user Colobreathe 1,662,500 IU inhalation powder, hard capsules 
Navodilo za uporabo Colobreathe 1.662.500 i.e. prašek za inhaliranje, trde kapsule natrijev kolistimetat
• Chest pain 
• krči,
patients 
Zdravljenje
Gastrointestinal disorders 
Psihiatrične motnje tesnoba
What measures are being taken to ensure the safe and effective use of Vpriv? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Vpriv?
The main measure of effectiveness was the improvement in anaemia, one of the symptoms of the disease, after 41 weeks. 
Glavno merilo učinkovitosti je bilo izboljšanje anemije, ki je eden od simptomov bolezni, po 41 tednih zdravljenja.
The European Commission granted a marketing authorisation valid throughout the European Union for Vpriv on 26 August 2010. 
Evropska komisija je dovoljenje za promet z zdravilom Vpriv, veljavno po vsej Evropski uniji, izdala 26. avgusta 2010.
The dose can be adjusted according to each patient's symptoms and response to treatment. 
Odmerek se lahko prilagodi glede na simptome vsakega posameznega bolnika in njegov odziv na zdravljenje.
What benefit has Vpriv shown during the studies? 
Kakšne koristi je zdravilo Vpriv izkazalo med študijami?
Other information about Vpriv 
Druge informacije o zdravilu Vpriv
The most serious side effects are hypersensitivity (allergic) reactions. 
Najresnejši neželeni učinki so preobčutljivostne (alergijske) reakcije.
Vpriv increased the amount of haemoglobin (the protein in red blood cells that carries oxygen) by an average of 1.6 grams per decilitre (from 11.4 g/dl) while imiglucerase increased the amount of haemoglobin by an average of 1.5 g/dl (from 10.6 g/dl). 
Zdravilo Vpriv je količino hemoglobina (beljakovine v rdečih krvnih celicah, ki prenašajo kisik) v povprečju povečalo za 1,6 grama na deciliter (z vrednosti 11,4 g/dl), medtem ko je imigluceraza količino hemoglobina v povprečju povečala za 1,5 g/dl (z vrednosti 10,6 g/dl).
The recommended dose of Vpriv is 60 units/kg bodyweight, which is given as a one-hour infusion once every two weeks. 
Priporočeni odmerek zdravila Vpriv je 60 enot/kg telesne mase, ki se daje v obliki enourne infuzije enkrat vsake dva tedna.
The study also looked at control of other signs of the disease such as the increase in the number of platelets in the blood, and the reduction of the size of the liver and spleen. 
V študiji so proučevali tudi nadzor nad drugimi znaki bolezni, kot sta povečanje števila trombocitov v krvi ter zmanjšanje velikosti jeter in vranice.
The first three infusions are given in hospital, but subsequent infusions may be given at home in patients who tolerate the medicine well. 
Prve tri infuzije se dajo v bolnišnici, a se lahko pri bolnikih, ki zdravilo dobro prenašajo, naslednje infuzije dajo v domači oskrbi.
In one main study involving 35 patients (including 9 children) with type 1 Gaucher disease, Vpriv was compared with imiglucerase (another medicine for Gaucher disease). 
V eni glavni študiji, v katero je bilo vključenih 35 bolnikov (vključno z devetimi otroki) z Gaucherjevo boleznijo tipa 1, so zdravilo Vpriv primerjali z imiglucerazo (drugim zdravilom za zdravljenje Gaucherjeve bolezni).
For more information about treatment with Vpriv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Vpriv preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is the risk associated with Vpriv? 
Kakšna tveganja so povezana z zdravilom Vpriv?
The summary of the opinion of the Committee for Orphan Medicinal Products for Vpriv is available on the Agency's website under EMA website/Find medicine/Human medicines/Rare disease designations. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Vpriv je na voljo na spletni strani agencije EMA website/Find medicine/Human medicines/Rare disease designations.
This document is a summary of the European public assessment report (EPAR) for Vpriv. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Vpriv.
Velaglucerase alfa replaces the missing enzyme in Gaucher disease, helping to break down glucocerebroside and stopping it building up in the body. 
Velagluceraza alfa nadomesti manjkajoči encim pri Gaucherjevi bolezni tako, da pomaga razgraditi glukocerebrozid in zaustavi njegovo kopičenje v telesu.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vpriv. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The CHMP decided that Vpriv's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Vpriv večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Because the number of patients with Gaucher disease is low, the disease is considered ‘rare', and Vpriv was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 June 2010. 
Ker je bolnikov z Gaucherjevo boleznijo malo, velja ta bolezen za redko, zato je bilo zdravilo Vpriv 9. junija 2010 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Vpriv must not be used in people who have a severe allergic reaction to velaglucerase alfa or any of the other ingredients. 
Zdravila Vpriv ne smejo uporabljati osebe, ki imajo hudo alergijsko reakcijo na velaglucerazo alfa ali katero koli drugo sestavino zdravila.
Why has Vpriv been approved? 
Zakaj je bilo zdravilo Vpriv odobreno?
Vpriv is used in patients who have type 1 Gaucher disease, the type that usually affects the liver, spleen and bones. 
Zdravilo Vpriv se uporablja pri bolnikih, ki imajo Gaucherjevo bolezen tipa 1, ki običajno prizadene jetra, vranico in kosti.
The study also showed that Vpriv is as effective as imiglucerase in controlling other signs of Gaucher disease. 
Študije so pokazale, da je zdravilo Vpriv enako učinkovito kot imigluceraza tudi pri nadzoru drugih simptomov Gaucherjeve bolezni.
Vpriv is a medicine that contains the active substance velaglucerase alfa. 
Vpriv je zdravilo, ki vsebuje zdravilno učinkovino velagluceraza alfa.
Home infusions should be supervised by a healthcare professional trained in emergency measures. 
Infundiranje na domu se mora izvajati pod nadzorom zdravstvenega osebja, ki je izurjeno za izredno ukrepanje.
Vpriv is used for the long-term treatment of patients with Gaucher disease. 
Zdravilo Vpriv se uporablja za dolgotrajno zdravljenje bolnikov z Gaucherjevo boleznijo.
It is available as a powder that is made up into a solution for infusion (drip) into a vein. 
Na voljo je v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
The company that markets Vpriv will provide educational material to all doctors and patients expected to use Vpriv, informing them of how to manage the risk of infusion-related reactions when the medicine is given at home. 
Družba, ki trži zdravilo Vpriv, bo vsem zdravnikom in bolnikom, ki naj bi uporabljali to zdravilo, priskrbela izobraževalno gradivo z navodili, kako obvladati tveganja, povezana z infundiranjem, če se zdravilo daje v domači oskrbi.
The most common side effects with Vpriv (seen in more than 1 patient in 10) are infusion-related reactions, which include headache, dizziness, hypotension (low blood pressure), hypertension (high blood pressure), nausea (feeling sick), asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature. 
Najpogostejši neželeni učinki zdravila Vpriv (opaženi pri 1 bolniku od 10) so povezani z infundiranjem in vključujejo glavobol, omotico, hipotenzijo (nizek krvni tlak), hipertenzijo (visok krvni tlak), navzejo (slabost), astenijo (šibkost) ali utrujenost ter pireksijo (povišano telesno temperaturo).
The full EPAR for Vpriv can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Vpriv je na voljo na spletni strani agencije EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Vpriv treatment should be supervised by a doctor experienced in managing patients with Gaucher disease. 
Zdravljenje z zdravilom Vpriv mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov z Gaucherjevo boleznijo.
Without the enzyme, glucocerebroside builds up in the body, typically in the liver, spleen and bone, which produces the symptoms of the disease: anaemia (low red blood cell counts), tiredness, easy bruising and a tendency to bleed, an enlarged spleen and liver, and bone pain and breaks. 
Ob odsotnosti encima se glukocerebrozid kopiči v telesu, običajno v jetrih, vranici in kostnem mozgu, to pa vodi do nastanka simptomov bolezni: anemije (znižanega števila rdečih krvničk), utrujenosti, povečane verjetnosti za nastanek hematomov in nagnjenosti h krvavitvam, povečane vranice in jeter ter bolečin v kosteh in zlomov kosti.
Vpriv was as effective as imiglucerase at reducing anaemia. 
Zdravilo Vpriv je bilo pri zmanjševanju anemije enako učinkovito kot imigluceraza.
For the full list of all side effects and restrictions with Vpriv, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Vpriv glejte navodilo za uporabo.
What is Vpriv used for? 
Za kaj se uporablja zdravilo Vpriv?
Gaucher disease occurs because of the lack of an enzyme called glucocerebrosidase. 
Gaucherjeva bolezen se pojavi zaradi pomanjkanja encima glukocerebrozidaze.
How has Vpriv been studied? 
Kako je bilo zdravilo Vpriv raziskano?
Gaucher disease is a rare inherited disorder, in which people do not have enough of an enzyme called glucocerebrosidase, which normally breaks down a fat called glucocerebroside. 
Gaucherjeva bolezen je redka dedna napaka, pri kateri bolniku primanjkuje encima glukocerebrozidaze, ki razgrajuje maščobni odpadni produkt, imenovan glukocerebrozid.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vpriv have also been included in the summary of product characteristics and the package leaflet. 
V povzetek glavnih značilnosti zdravila Vpriv in navodila za njegovo uporabo so bili vključeni priporočila in previdnostni ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki za njegovo varno in učinkovito uporabo.
How is Vpriv used? 
Kako se zdravilo Vpriv uporablja?
What is Vpriv? 
Kaj je zdravilo Vpriv?
How does Vpriv work? 
Kako zdravilo Vpriv deluje?
They are usually temporary. 
Navadno so prehodni.
Your doctor will discuss this with you. 
O tem se bo zdravnik pogovoril z vami.
• Your doctor will advise you of the risks and benefits of taking Ontruzant during pregnancy. 
• Zdravnik vam bo svetoval glede tveganj in koristi jemanja zdravila Ontruzant med nosečnostjo.
Sometimes, symptoms may improve and then get worse later. 
Včasih se lahko simptomi izboljšajo in pozneje spet poslabšajo.
Appropriate aseptic technique should be used. 
Uporabljati morate ustrezno aseptično tehniko.
Allow the vial to stand undisturbed for approximately 5 minutes. 
Viala naj stoji pri miru približno 5 minut.
The following information is intended for healthcare professionals only 
Naslednje informacije so namenjene samo zdravstvenemu osebju:
Children and adolescents Ontruzant is not recommended for anyone under the age of 18 years. 
Otroci in mladostniki Uporaba zdravila Ontruzant ni priporočljiva za mlajše od 18 let.
During pregnancy: 
V nosečnosti:
AUCss, 0-21 days 
AUCss, 0-21 dni
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 15 November 2017 
Datum prve odobritve: 15. november 2017
The number of infusions you receive will depend on how you respond to the treatment. 
Število infuzij, ki jih boste prejeli, bo odvisno od vašega odziva na zdravljenje.
Before starting the treatment your doctor will determine the amount of HER2 in your tumour. 
Pred začetkom zdravljenja bo zdravnik ugotovil količino HER2 v vašem tumorju.
Unopened vials: 4 years. 
Neodprte viale: 4 leta
The majority of the deaths were due to events related to the underlying cancer. 
Večina smrti je bila posledica dogodkov, povezanih z obstoječim rakom.
The bioactivity of D7D and the clinical impact of the elevation of this metabolite was unclear. 
Biološka aktivnost D7D in klinični vpliv zvišanja tega presnovka sta bila nejasna.
This helps your medicine work as well as it can. 
To omogoči vašemu zdravilo delovati kar najbolj učinkovito.
Doses up to this level were well tolerated. 
Odmerke do te ravni so bolniki dobro prenašali.
Therefore your doctor may decide to continue to check your heart functions, even after you finish treatment. 
Zato se bo mogoče zdravnik odločil za nadaljevanje spremljanja delovanja vašega srca tudi po končanem zdravljenju.
(increased muscle tone or tension) 
(zvečan mišični tonus ali napetost),
The primary endpoint was overall survival which was defined as the time from the date of randomization to the date of death from any cause. 
Primarni končni cilj preskušanja je bilo celotno preživetje, ki je bilo definirano kot čas od datuma randomizacije do datuma smrti ne glede na vzrok.
Ontruzant can cause breathing difficulties, especially when it is first given. 
Zdravilo Ontruzant lahko povzroča težave z dihanjem, posebno takrat, ko vam ga dajo prvič.
Volume (mL) = 
Volumen (ml) =
It is not known whether trastuzumab can affect reproductive capacity. 
Ni znano, ali trastuzumab lahko škodljivo vpliva na sposobnost za razmnoževanje.
These tissues were fixed in formalin or Bouin's fixative. 
Tkiva so bila fiksirana v formalinu ali Bouinovem fiksativu.
At the time of a safety update after a median of 3.5-3.8 years follow-up, an analysis of DFS reconfirms the magnitude of the benefit shown in the definitive analysis of DFS. 
Ob posodobitvi varnosti po medianem spremljanju 3,5-3,8 leta je analiza DFS spet potrdila velikost koristi, prikazane v končni analizi DFS.
AUC0-21days 
AUC0-21 dni
All doses should be taken at the right time every week or every three weeks (depending on your dosing schedule). 
Vse odmerke morate prejeti pravočasno ali vsak teden ali vsake 3 tedne (odvisno od vaše sheme odmerjanja).
For time to response and duration of response no difference could be recorded between the arms. 
Glede časa do odziva in trajanja odziva med skupinama ni bilo razlik v času.
TTP = time to progression; "ne" indicates that it could not be estimated or it was not yet reached. 
TTP = čas do napredovanja bolezni; “no” - ni bilo mogoče oceniti ali pa še ni bilo doseženo.
Other side effects that have been reported with Ontruzant use (frequency cannot be estimated from the available data): 
Drugi neželeni učinki, o katerih so poročali pri uporabi zdravila Ontruzant (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov):
• you have ever had or are currently using a medicine called doxorubicin or epirubicin (medicines used to treat cancer). 
• ste kadar koli uporabljali ali trenutno uporabljate zdravilo, ki se imenuje doksorubicin ali epirubicin (zdravili, ki se uporabljata za zdravljenje raka).
The majority of these events occur during or within 2.5 hours of the start of the first infusion. 
Večina teh dogodkov nastopi znotraj 2,5 ure po začetku prve infuzije.
Overexpression of HER2 is observed in 20%-30% of primary breast cancers. 
Čezmerno izražanje HER2 opažamo pri 20 %-30 % primerov primarnega raka dojk.
Your doctor will closely supervise your therapy. 
Vaš zdravnik bo natančno nadzoroval vaše zdravljenje.
Study MO16419 
Študija MO16419.
Your doctor will prescribe a dose and treatment regimen that is right for you. 
Zdravnik vam bo predpisal odmerek in shemo zdravljenja, ki sta prava za vas.
Initial improvement followed by clinical deterioration and delayed reactions with rapid clinical deterioration have also been reported. 
Poročali so tudi o začetnem izboljšanju, ki mu sledi klinično poslabšanje in zapoznele reakcije s hitrim kliničnim poslabšanjem.
This could be more serious if you are already breathless. 
Težave so lahko resnejše, če ste že zasopli.
Your doctor will monitor your heart regularly during and after treatment but you should tell your doctor immediately if you notice any of the above symptoms. 
Zdravnik bo med zdravljenjem in po njem redno nadzoroval vaše srce, vi pa morate zdravniku nemudoma povedati, če opazite katerega od zgoraj navedenih simptomov.
The t1/2 decreases with decreasing concentrations within a dosing interval (see Table 16). 
t1/2 se zmanjšuje z zmanjševanjem koncentracij znotraj intervala odmerkov (glejte preglednico 16).
Patients should be warned of the possibility of such a late onset and should be instructed to contact their physician if these symptoms occur. 
Bolnike moramo posvariti pred možnostjo takega poznega nastopa in jim dati navodila, naj se obrnejo na svojega zdravnika, če se pojavijo ti simptomi.
Interruption or slowing the rate of the infusion may help control such symptoms. 
Prekinitev ali upočasnitev hitrosti infuzije lahko pomaga pri nadzoru teh simptomov.
Greater than 70% of patients enrolled exhibited 3+ overexpression. 
Več kot 70 % vključenih bolnikov je kazalo čezmerno izražanje 3+.
These effects mainly occur with the first intravenous infusion (“drip” into your vein) and during the first few hours after the start of the infusion. 
Ti učinki se pojavijo predvsem med prvo intravensko (“kapalno”) infuzijo v vašo veno in prvih nekaj ur po začetku infuzije.
Some of these symptoms can be serious and some patients have died (see section 2 under “Warnings and precautions”). 
Nekateri od teh simptomov so lahko resni in opisani so primeri smrti (glejte poglavje 2 pod “Opozorila in previdnostni ukrepi”).
Patients classified as staining 2+ or 3+ were included, while those staining 0 or 1+ were excluded. 
Bolnike, ki so jih razvrstili kot obarvanje 2+ ali 3+, so vključili, tiste, ki so se obarvali z 0 ali 1+, pa izključili.
• abnormally low oxygen levels in the blood 
• nenormalno nizka raven kisika v krvi,
Therefore, no constant value for half-life of trastuzumab can be deduced. 
Zato ni bilo mogoče določiti konstantne vrednosti za razpolovno dobo trastuzumaba.
Do not dilute with glucose solutions since these cause aggregation of the protein. 
Ne redčite z raztopinami glukoze, ker povzročajo agregacijo beljakovin.
If you stop using Ontruzant 
Če ste prenehali uporabljati zdravilo Ontruzant
SISH technology is however, recommended to allow for the parallel evaluation of tumor histology and morphology. 
Vendar pa priporočajo tehnologijo SISH za vzporedno ocenjevanje histologije in morfologije tumorja.
The presence of trastuzumab in the serum of infant monkeys was not associated with any adverse effects on their growth or development from birth to 1 month of age. 
Prisotnost trastuzumaba v serumu opičjih mladičev ni bila povezana z nobenimi neželenimi učinki na njihovo rast ali razvoj od kotitve do enega meseca starosti.
HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. 
HER2 najdemo v velikih količinah na površini nekaterih rakastih celic, kjer spodbuja njihovo rast.
A study of trehalose, a major formulation excipient, did not reveal any toxicities. 
Študija trehaloze, glavne pomožne snovi zdravila, ni razkrila nikakršne toksičnosti.
In this section, the following categories of frequency have been used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Ontruzant should only be given by a doctor or nurse. 
Zdravilo Ontruzant lahko daje samo zdravnik ali medicinska sestra.
Infusion solutions should be used immediately after dilution. 
Infuzijske raztopine je treba porabiti takoj po razredčenju.
Caution should be exercised for pneumonitis, especially in patients being treated concomitantly with taxanes. 
Pozorni moramo biti na pnevmonitis, posebno pri bolnikih, ki jih sočasno zdravimo s taksani.
• you suffer from breathlessness., especially if you are currently using a taxane. 
• pri sebi opažate zasoplost, posebno še, če se trenutno zdravite s taksani.
The results of these simulations indicate that at least 95% of patients will reach concentrations that are <1 µg/mL (approximately 3% of the population predicted Cmin,ss, or about 97% washout) by 7 months. 
Rezultati teh simulacij kažejo, da bo vsaj 95 % bolnikov po 7 mesecih doseglo koncentracije < 1 µg/ml (približno 3 % Cmin,ss, predvidene za populacijo, ali okrog 97-odstotno spiranje).
The extracellular domain of the receptor (ECD, p105) can be shed into the blood stream and measured in serum samples. 
Zunajcelična domena receptorja (ECD, p105) se lahko odcepi v krvni obtok in jo lahko merimo v vzorcih seruma.
Always keep this medicine in the closed original pack at a temperature of 2ºC - 8ºC in a refrigerator. 
To zdravilo vedno hranite v zaprtem originalnem pakiranju pri temperaturi 2 ºC - 8 ºC v hladilniku.
The median duration of follow-up in the trastuzumab arm was 3.8 years. 
Mediano trajanje spremljanja v skupini s trastuzumabom je bilo 3,8 leta.